FREMONT, CA — November 13, 2025 — Leads & Copy — Diversified immunotherapeutics company Tivic Health Systems, Inc. (Nasdaq:TIVC) announced today it has optimized key device and treatment parameters including frequency, amplitude, electrode positioning, and duration of stimulation as a result of its collaborative study with The Feinstein Institutes for Medical Research at Northwell Health.
Physiological measurements taken before, during, and after ncVNS treatment found that personalizing the frequency of ncVNS stimulation to each study subject resulted in a 46% increase in heart rate variability, which was 8.9x more effective than applying the same frequency to all subjects. The optimal ncVNS frequency for each subject was found to be different between visits, indicating the importance of personalizing the stimulation parameters before each treatment.
Certain placement and configurations of electrodes were found to be more effective than others, with some placements increasing heart rate variability and others markedly reducing heart rate variability. Four minutes of ncVNS stimulation was sufficient to drive a large increase in heart rate variability and was more effective than twenty minutes of stimulation.
Tivic’s study demonstrated that specific parameters could reproducibly impact outcomes. While previous studies of non-invasive VNS devices have reported mixed results for autonomic nervous system changes.
Jennifer Ernst, CEO of Tivic Health, stated that their findings advance the field of neurostimulation by underscoring the importance of stimulation frequency personalization, laterality and placement of stimulation electrodes, and duration of treatment. Ernst also stated that while these results were in healthy subjects, this data combined with their past studies suggest their ncVNS approach may have clinical utility in several very large patient populations including ischemic stroke, post-traumatic stress disorder, and inflammatory diseases, among others. Ernst further stated that their mission is to harness the immune system to improve clinical outcomes and save lives and that they believe that this new data will enable them to unlock valuable new opportunities that can be developed either in house or with partners as funding is allocated across a growing pipeline of late-, mid- and early stage product candidates.
Tivic’s dual platform utilizes the body’s biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system.
Tivic’s biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company’s lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track and Orphan Drug designations and is in late-stage development.
Tivic’s bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic’s approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices.
Investor Contact:
Hanover International, Inc.
ir@tivichealth.com
Media Contact:
Deanne Eagle or Laura Min Jackson
media@tivichealth.com
Source: Tivic Health Systems, Inc.
